Cargando…
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COV...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115603/ https://www.ncbi.nlm.nih.gov/pubmed/35584816 http://dx.doi.org/10.1136/bmj-2021-069676 |
_version_ | 1784709955104800768 |
---|---|
author | Ayoubkhani, Daniel Bermingham, Charlotte Pouwels, Koen B Glickman, Myer Nafilyan, Vahé Zaccardi, Francesco Khunti, Kamlesh Alwan, Nisreen A Walker, A Sarah |
author_facet | Ayoubkhani, Daniel Bermingham, Charlotte Pouwels, Koen B Glickman, Myer Nafilyan, Vahé Zaccardi, Francesco Khunti, Kamlesh Alwan, Nisreen A Walker, A Sarah |
author_sort | Ayoubkhani, Daniel |
collection | PubMed |
description | OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. MAIN OUTCOME MEASURE: Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. RESULTS: Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. CONCLUSIONS: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed. |
format | Online Article Text |
id | pubmed-9115603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91156032022-05-19 Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study Ayoubkhani, Daniel Bermingham, Charlotte Pouwels, Koen B Glickman, Myer Nafilyan, Vahé Zaccardi, Francesco Khunti, Kamlesh Alwan, Nisreen A Walker, A Sarah BMJ Research OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. MAIN OUTCOME MEASURE: Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. RESULTS: Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. CONCLUSIONS: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed. BMJ Publishing Group Ltd. 2022-05-18 /pmc/articles/PMC9115603/ /pubmed/35584816 http://dx.doi.org/10.1136/bmj-2021-069676 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Ayoubkhani, Daniel Bermingham, Charlotte Pouwels, Koen B Glickman, Myer Nafilyan, Vahé Zaccardi, Francesco Khunti, Kamlesh Alwan, Nisreen A Walker, A Sarah Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title_full | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title_fullStr | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title_full_unstemmed | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title_short | Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
title_sort | trajectory of long covid symptoms after covid-19 vaccination: community based cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115603/ https://www.ncbi.nlm.nih.gov/pubmed/35584816 http://dx.doi.org/10.1136/bmj-2021-069676 |
work_keys_str_mv | AT ayoubkhanidaniel trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT berminghamcharlotte trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT pouwelskoenb trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT glickmanmyer trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT nafilyanvahe trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT zaccardifrancesco trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT khuntikamlesh trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT alwannisreena trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy AT walkerasarah trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy |